You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

October 2, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Pertuzumab regimen extends lives in HER2-positive breast cancer

Adding pertuzumab (Perjeta, Roche) to trastuzumab (Herceptin, Genentech) and docetaxel chemotherapy extended the lives of patients with previously untreated HER2-positive metastatic breast cancer by 15.7 months compared to trastuzumab and chemotherapy, according to new data. » Read more about this new finding

FDA approves updated label changes for Chantix

FDA has approved updated label changes for the smoking cessation drug, varenicline (Chantix, Pfizer).
» Read more on Chantix label changes

Continuing Education

MTM essentials for anticoagulant management in cardiovascular disease

This month's article is the seventh in a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to review the pharmacological properties, safety and efficacy, and risk/benefit profile for the various anticoagulant medications used in cardiovascular diseases.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT10-VXP89.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Sepsis marketplace represents untapped opportunity for big pharma

In 2011 alone, the treatment of hospitalized sepsis patients cost $20.3 billion, accounting for a staggering 5.2% of all hospitalization costs and making it the most expensive condition treated in US hospitals. » See more

 

Related Articles

Mammography cost includes follow-up

CVS: Expansion of MinuteClinics to offset tobacco revenue loss

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group